基因组胺H3受体的活性恢复突变增加了构成性活性,并降低了结构稳定性
Ami Nakajima1, Hiroto Kaneko1, Kosuke Oyama1
1Department of Biological Science and Technology, Tokyo University of Science, Tokyo, Japan.
Protein science : a publication of the Protein Society
|December 22, 2025
概括
特定的突变通过破坏其结构来增强组分胺H3受体 (H3R) 的构成性活性. 这些发现揭示了结构不稳定性和GPCR激活之间的联系.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 组胺H3受体 (H3R),一种G蛋白结合受体 (GPCR),调节神经递质释放.
- 了解特定残留物在H3R激活中的功能作用至关重要.
- 以前的研究发现了恢复酵母信号的突变,但它们的机制仍然不清楚.
研究的目的:
- 为了研究特定的H3R残留物的功能作用.
- 阐明发现突变增强受体活性的机制.
- 探索H3R中的结构稳定性和构成性激活之间的关系.
主要方法:
- 针对H3R和H1R的局部导向突变发生.
- 在酵母和哺乳动物细胞中的功能测试.
- 放射性结测定和快速标签自由场电化学扫描 (FSEC) 分析.
主要成果:
- 鉴定出的突变 (L73M,F193S,S359Y,C415R) 增强了H3R.的构成性活性.
- 突变协同作用,将构造平衡转移到活跃状态.
- 构成性活性增加与结构稳定性降低和基因组胺亲和力的最小变化相关.
结论:
- 结构不稳定与H3R的构成性激活密切相关.
- 这些突变的功能后果是受体依赖的.
- GPCR激活是一个复杂的过程,涉及结构调制和结构稳定.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
890
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
890
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
The Two-State Receptor Model
3.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.0K
GPCRs Regulate Adenylyl Cylase Activity
7.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.2K
GPCR Desensitization
7.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.3K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.3K


